Phenotypes Associated with This Genotype

Genotype
MGI:5427573

• Allelic Composition: Nrbp1^tm1.1Dja/Nrbp1^tm1.2Dja; Gt(ROSA)26Sor^{tm1(cre/ERT)Brn}/Gt(ROSA)26Sor⁺
• Genetic Background: involves: 129P2/OlaHsd * 129S4/SvJaeSor * 129S7/SvEvBrd * C57BL/6J

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

respiratory system

increased lung carcinoma incidence ( J:184685 )

• in tamoxifen-treated mice

mortality/aging

decreased tumor-free survival time ( J:184685 )

• moribund as early as 3 days post tamoxifen treatment

• 75% of mice die 9 days after tamoxifen treatment

• mice treated with a low dose of tamoxifen exhibit increased death associated with tumorigenesis

digestive/alimentary system

abnormal enterocyte proliferation ( J:184685 )

• tamoxifen-treated mice exhibit increased cell proliferation in the intestinal epithelium compared with control mice

abnormal intestine morphology ( J:184685 )

• loss of architecture in tamoxifen-treated mice with reduction in numbers of differentiated cells, cells showing dysplastic nuclear atypia, widespread crypt elongation, increased crypt fission and reduction in villous length

abnormal intestinal mucosa morphology ( J:184685 )

• in tamoxifen-treated mice

abnormal intestinal enteroendocrine cell morphology ( J:184685 )

• reduced numbers in tamoxifen-treated mice

abnormal intestine goblet cell morphology ( J:184685 )

• tamoxifen-treated mice exhibit a decrease of Alcian Blue positive goblet cells compared with control mice

abnormal crypts of Lieberkuhn morphology ( J:184685 )

• elongated in tamoxifen-treated mice

ectopic Paneth cells ( J:184685 )

• altered distribution in tamoxifen-treated mice

intestinal edema ( J:184685 )

• in tamoxifen-treated mice

distended stomach ( J:184685 )

• in tamoxifen-treated mice

increased gastrointestinal tumor incidence ( J:184685 )

• in 6 of 16 tamoxifen-treated mice, 2 of which are adenomas with high-grade dysplasia and 2 are invasive adenocarcinoma

• 5 of 6 tumors are located in the caecum

neoplasm

increased tumor incidence ( J:184685 )

• tamoxifen-treated mice exhibit increased incidence of tumorigenesis, including lymphomas/leukemias and solid tumors (angiosarcoma, gastrointestinal adenoma, gastrointestinal adenocarcinoma and lung carcinoma)

increased gastrointestinal tumor incidence ( J:184685 )

• in 6 of 16 tamoxifen-treated mice, 2 of which are adenomas with high-grade dysplasia and 2 are invasive adenocarcinoma

• 5 of 6 tumors are located in the caecum

increased leukemia incidence ( J:184685 )

• in tamoxifen-treated mice

increased lymphoma incidence ( J:184685 )

• in tamoxifen-treated mice

increased lung carcinoma incidence ( J:184685 )

• in tamoxifen-treated mice

liver/biliary system

abnormal liver morphology ( J:184685 )

• tamoxifen-treated mice exhibit zone 3 hydropic changes indicative of malnutrition unlike control mice

homeostasis/metabolism

intestinal edema ( J:184685 )

• in tamoxifen-treated mice

cellular

abnormal intestinal enteroendocrine cell morphology ( J:184685 )

• reduced numbers in tamoxifen-treated mice

abnormal intestine goblet cell morphology ( J:184685 )

• tamoxifen-treated mice exhibit a decrease of Alcian Blue positive goblet cells compared with control mice

abnormal enterocyte proliferation ( J:184685 )

• tamoxifen-treated mice exhibit increased cell proliferation in the intestinal epithelium compared with control mice

endocrine/exocrine glands

abnormal crypts of Lieberkuhn morphology ( J:184685 )

• elongated in tamoxifen-treated mice

ectopic Paneth cells ( J:184685 )

• altered distribution in tamoxifen-treated mice